Overall survival in patients with hormone receptor-positive, HER2
4.6 (756) · € 13.99 · Auf Lager
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - The Lancet
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Hormone Receptor Positive (ER+/PR+) Recurrence & Survival Data
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer - ScienceDirect
Cancers, Free Full-Text
Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All - touchONCOLOGY
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - ScienceDirect
Estrogen Receptor Status on Survival in breast cancer
ASCO GUIDELINES Bundle - HR-Positive, HER2-Negative Metastatic Breast Cancer Endocrine Treatment and Targeted Therapy
Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early HER2-Negative Breast Cancer - The ASCO Post
Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies - ScienceDirect
Patients with Bone-Only Metastatic Breast Cancer
